The prevalence of loss of imprinting of H19 and IGF2 at birth

被引:32
作者
Rancourt, Rebecca C. [1 ,2 ]
Harris, Holly R. [1 ,3 ]
Barault, Ludovic [1 ]
Michels, Karin B. [1 ,2 ]
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA
[3] Karolinska Inst, Natl Inst Environm Med, Div Nutr Epidemiol, Stockholm, Sweden
基金
美国国家卫生研究院;
关键词
allele-specific expression; DNA methylation; genomic; cohort; BECKWITH-WIEDEMANN-SYNDROME; UNIPARENTAL DISOMY; CHROMOSOME; 11P15; GENE-EXPRESSION; WILMS-TUMOR; METHYLATION; BREAST; REGION; LOCUS; HYPOMETHYLATION;
D O I
10.1096/fj.12-225284
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Imprinted genes are monoallelically expressed according to the parent of origin and are critical for proper placental and embryonic development. Disruption of methylation patterns at imprinted loci resulting in loss of imprinting (LOI) may lead to serious imprinting disorders (e.g., Beckwith-Wiedemann syndrome) and is described in some cancers (e.g., Wilms' tumor). As most research has focused on children with cancer or other abnormal phenotypes, the imprinting status in healthy infants at birth has not been characterized. We examined the prevalence of H19 and IGF2 LOI at birth by allele-specific expression assays analysis on 114 human individuals. Overall expression and methylation analyses were performed on a subset of samples. We found that LOI of H19 was observed for 4% of individuals in cord blood and 3.3% in placenta, and for IGF2 of 22% of individuals in the cord blood and 0% in placenta. Interestingly, LOI status did not correspond to aberrant methylation levels of the imprinted DMRs or with changes in overall gene expression for the majority of individuals. Our observations suggest that LOI is present in phenotypically healthy infants. Determining a normal human epigenotype range is important for discovering factors required to maintain a healthy pregnancy and embryonic development.Rancourt, R. C., Harris, H. R., Barault, L., Michels, K. B. The prevalence of loss of imprinting of H19 and IGF2 at birth.
引用
收藏
页码:3335 / 3343
页数:9
相关论文
共 46 条
[1]   Single-nucleotide polymorphism analysis by pyrosequencing [J].
Ahmadian, A ;
Gharizadeh, B ;
Gustafsson, AC ;
Sterky, F ;
Nyrén, P ;
Uhlén, M ;
Lundeberg, J .
ANALYTICAL BIOCHEMISTRY, 2000, 280 (01) :103-110
[2]   Elevated placental expression of the imprinted PHLDA2 gene is associated with low birth weight [J].
Apostolidou, S. ;
Abu-Amero, S. ;
O'Donoghue, K. ;
Frost, J. ;
Olafsdottir, O. ;
Chavele, K. M. ;
Whittaker, J. C. ;
Loughna, P. ;
Stanier, P. ;
Moore, G. F. .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2007, 85 (04) :379-387
[3]   Leukocyte DNA as Surrogate for the Evaluation of Imprinted Loci Methylation in Mammary Tissue DNA [J].
Barault, Ludovic ;
Ellsworth, Rachel E. ;
Harris, Holly R. ;
Valente, Allyson L. ;
Shriver, Craig D. ;
Michels, Karin B. .
PLOS ONE, 2013, 8 (02)
[4]   Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development [J].
Brown, Keith W. ;
Power, Frances ;
Moore, Beth ;
Charles, Adrian K. ;
Malik, Karim T. A. .
MOLECULAR CANCER RESEARCH, 2008, 6 (07) :1114-1123
[5]   Mutation analysis of H19 and NAP1L4 (hNAP2) candidate genes and IGF2 DMR2 in Beckwith-Wiedemann syndrome [J].
Catchpoole, D ;
Smallwood, AV ;
Joyce, JA ;
Murrell, A ;
Lam, W ;
Tang, T ;
Munroe, D ;
Reik, W ;
Schofield, PN ;
Maher, ER .
JOURNAL OF MEDICAL GENETICS, 2000, 37 (03) :212-215
[6]  
Charalambous Marika, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P3, DOI 10.1097/MED.0b013e328013daa2
[7]   Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability [J].
Cui, HM ;
Horon, IL ;
Ohlsson, R ;
Hamilton, SR ;
Feinberg, AP .
NATURE MEDICINE, 1998, 4 (11) :1276-1280
[8]   Loss of IGF2 imprinting:: A potential marker of colorectal cancer risk [J].
Cui, HM ;
Cruz-Correa, M ;
Giardiello, FM ;
Hutcheon, DF ;
Kafonek, DR ;
Brandenburg, S ;
Wu, YQ ;
He, XB ;
Powe, NR ;
Feinberg, AP .
SCIENCE, 2003, 299 (5613) :1753-1755
[9]  
Cui HM, 2002, CANCER RES, V62, P6442
[10]  
DAVIES SM, 1994, CANCER RES, V54, P2560